Kornimate/medical-research-clean huggingface dataset:
fluzoparib combined with bevacizumab in psroc previously treated with parpi

Conditions: Ovarian Cancer

Summary: there are more and more parpi(parp inhibitors) resistance for ovarian cancer patients after previous use of parp inhibitors. basic studies have found that there is synergistic effect of bevacizumab combined with parpi. therefore we designed the study to include 42 ovarian cancer patients who had parpi for at least half a year and then relapsed (platinum-sensitive, previously 1-3 lines of chemotherapy). after getting complete remission or partial remission with chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used for maintenance treatment. the progression-free survival, orr, dcr, dor, and safety were evaluated based on recist v1.1.

genetic testing of tissue samples before and after the maintenance therapy were also used to further explore the pattern of gene mutations and the subgroups who may benefit.

Eligibility criteria:
inclusion criteria: 1. ovarian cancer patients with histopathological type: low/high grade serous carcinoma, endometrioid carcinoma,had received platinum-based regimens for at least 1-3 lines after primary cytoreductive surgery. 2. the patient had at least one measurable lesion according to the recist v1.1 criteria. 3. the time from the last cycle of chemotherapy to relapse/progression should be more than 6 months. 4. ecog score 0\~1,age 18\~75 years old 5. the serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial 6. cbc hb≥90g/l, anc≥1.5×109/l, plt≥100×109/l, 7. serum alt≤3×ul, ast≤3×uln#serum creatinine≤1.5×uln# exclusion criteria: 1. had used bevacizumab within 6 months of enrollment 2. has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated. the patients had untreated cns metastases. 3. the patient had recent intestinal obstruction, gastrointestinal perforation within 3 months, uncontrolled high blood pressure after medication (systolic blood pressure ≥140mmhg or diastolic blood pressure ≥90mmhg), moderate to severe cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), moderate to severe deep vein thrombosis and moderate to severe pulmonary embolism occurred within 6 months before enrollment. patient with coagulation dysfunction. 4. myocardial infarction, severe arrhythmia and nyha (new york heart association)≥2 for congestive heart failure 5. activity or uncontrol severe infection

Keywords: parp inhibitor fluzoparib bevacizumab platinum - sensitive recurrent eoc
comparison between oral clindamycin vs metronidazole for the treatment of abnormal vaginal flora in high risk pregnancies

Conditions: Abnormal Vaginal Flora; Clindamycin Vs Metronidazole; High Risk Pregnancies for Preterm Labor

Summary: abnormal vaginal flora is a risk factor for preterm labor. therefore, in high risk pregnancies for preterm labor the diagnosis and treatment of abnormal flora is indicated. clindamycin and metronidazole given orally are both acceptable treatments in these cases. the purpose of this study is to compare the effectiveness of clindamycin vs metronidazole for the treatment of abnormal vaginal flora in high risk pregnancies. for this purpose, pregnant women who are considered high risk for preterm labor and were diagnosed with abnormal vaginal flora will be randomly treated either with clindamycin or metronidazole. eradication of the abnormal flora and adverse effects will be monitored and compared


Eligibility criteria:
inclusion criteria: * pregnant women at increased risk for preterm labor (preterm cervical effacement, preterm uterine contractions, twins pregnancy, vaginal bleeding, past preterm delivery) * age above 18 years exclusion criteria: * known allergy to the tested antibiotics * antibacterial treatment in the week before the vaginal culture was taken * preterm premature rupture of membranes

Keywords: abnormal vaginal flora clindamycin vs metronidazole high risk pregnancies for preterm labor preterm labor late abortion bacterial vaginosis
comparison of treatments in venous insufficiency

Conditions: Venous Insufficiency

Summary: randomized controlled trial, a method used to implement the random allocation sequence is numbered containers. the aim of the study is to compare operative treatment, ultrasound guided laser ablation and ultrasound guided foam sclerotherapy in occluding/ablating of insufficiency in great saphenous trunks. on the grounds of the available data, the study hypothesis is that using laser or operative treatment more than 20 percent better outcome can be achieved compared to foam sclerotherapy.

in operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk. in intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. the probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. laser energy is delivered to seal the faulty vein. ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the thessari method) directly into the venous trunk under ultrasound control. in each group patients will use supportive treatment stockings 2 weeks after treatment. the patients in all groups are followed up one year by ultrasound scanning.

Eligibility criteria:
inclusion criteria: * patients with chronic superficial vein insufficiency * patient must be 20-70 years old * degree of difficulty of vein insufficiency c2-c4 * average diameter of refluxing great saphenous vein 4 -10 mm * patient is agreeable to the study exclusion criteria: * peripheral atherosclerotic occlusive disease * lymphoedema * severe concomitant disease * venous ulcers or unclassified skin changes * bmi more than 40 * pregnancy * allergy to the foam used in sclerotherapy or to local anaesthetics * coagulation disorder * bilateral vein insufficiency (equal symptoms)

Keywords: varicose veins, oedema
plantar sensation, balance, risk of falling and gait in patients with schizophrenia

Conditions: Plantar Sensation; Balance; Distorted; Fall; Gait Disorders, Neurologic

Summary: cerebellar vermis anomalies are present in schizophrenic individuals. this condition leads to postural balance problems. foot and ankle complex have a special role for maintaining balance. however, there is no study about this topic in schizophrenic individuals.


Eligibility criteria:
inclusion criteria: * diagnose of schizophrenia according to dsm-5 * being an individual in remission against the risk of having an attack * individuals who use the same psychotropic drugs for at least 4 weeks exclusion criteria: * individuals with physical and neurological comorbidities
biomarkers in patients with diffuse large b-cell lymphoma treated with combination chemotherapy with or without rituximab

Conditions: Lymphoma

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how well patients will respond to treatment. purpose: this research study is studying biomarkers in patients with diffuse large b-cell lymphoma treated with combination chemotherapy with or without rituximab.

objectives: * to identify genes predictive of clinical outcome (failure-free survival and overall survival) among patients with diffuse large b-cell lymphoma treated with chop or r-chop induction on ecog-e4494 using the nuclease protection assay for measuring gene expression in paraffin-embedded tissue. * to identify genes that change their prognostic profile with the addition of rituximab to chop chemotherapy. outline: this is a multicenter study. unstained formalin-fixed, paraffin-embedded samples are analyzed for gene expression via nuclease protection assay.

Eligibility criteria:
disease characteristics: * diagnosis of diffuse large b-cell lymphoma * treated with chop or r-chop on ecog-e4494 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: contiguous stage ii adult diffuse large cell lymphoma noncontiguous stage ii adult diffuse large cell lymphoma recurrent adult diffuse large cell lymphoma stage i adult diffuse large cell lymphoma stage iii adult diffuse large cell lymphoma stage iv adult diffuse large cell lymphoma
the murdock study registry and biorepository horizon 1.5

Conditions: Chronic Disease; Healthy Volunteers

Summary: the murdock study community registry and biorepository (horizon 1.5) aims to create a large-scale community registry and biorepository that can be used as a vehicle for future health services, epidemiologic, clinical trials and other omics-related research.

the murdock study community registry and biorepository's activities include enrolling approximately 50,000 participants who live in cabarrus county and/or kannapolis, north carolina. participants must consent to (1) use of the data provided by the participant through completion of the participant registry questionnaire for epidemiologic population characterization, (2) annual contact to update their murdock horizon 1.5 database record, (3) release of their medical information, including but not limited to demographic information, problem lists, medications, social and family history, and results of laboratory and other testing modalities from pre-existing paper or electronic health records or electronic health records that may become available in the future, (4) provision of a blood and urine sample, and (5) contact up to four times/year to request participation in additional research studies.

Eligibility criteria:
inclusion criteria: 1. a resident of cabarrus county and/or the city of kannapolis (and surrounding regions) for 6 or more months of the year 2. at least 18 years of age 3. able to understand and give written informed consent, or have a legal guardian or caregiver present to give informed consent by proxy (assent from a participant between ages 12-18 will be obtained when their parent or legal guardian consents on their behalf). 4. willing and able to participate in all 5 components of the registry and biorepository as described above in section iii exclusion criteria: 1. there are no exclusions to participation if all inclusion criteria have been met.

Keywords: biorepository biobank registry community biospecimens volunteers chronic disease longitudinal blood electronic health records follow-up
novel screening tools for the evaluation and management of malnourished children in the developing world

Conditions: Overweight, Obesity, Small for Gestational Age, Prematurity

Summary: the purpose of this study is to evaluate the accuracy of a new device that may be used for the evaluation and management of malnourished infants and children. the device will measure the levels of two hormones made by fat tissue: leptin and adiponectin.

the purpose of this study is to validate novel screening tools for the evaluation and management of malnourished infants and children in the developing world. the study will validate 2-d diffusion point of care testing (poct) for the rapid analysis of leptin and adiponectin, as these cytokines have been shown to predict mortality in malnourished infants and children. the study will enroll 20 participants, 10 overweight or obese adolescents presenting to the duke division of pediatric endocrinology outpatient clinics, in whom leptin is expected to be high and adiponectin low, and 10 premature or small for gestational age infants hospitalized in the duke transitional care nursery, in whom leptin is expected to be low and adiponectin high. informed consent will be obtained and 0-1 ml of blood will be collected and analyzed using the 2-d poct and commercial elisa assays. to reduce potential risks associated with venipuncture and/or finger or heelstick, blood draws for the purposes of this study will take place only when blood sampling is performed at the request of the primary provider, and an attempt will be made to utilize scavenge samples from infants where applicable. the poct will be validated against the commercial elisa assays. the investigators will analyze the results of each assay in addition to the means and standard deviations of the poct and elisas and will consider the poct valid if their variation from elisa is \<20%. the long-term goal of this project is to utilize this novel technology to identify and treat high-risk malnourished infants and children before they have reached the stage of critical, life-threatening illness.

Eligibility criteria:
inclusion criteria: * overweight or obese: inclusion criteria for these subjects will include: 1. age 8-17 years; 2. male or female; and 3. bmi \>85% for age. * premature or small for gestational age: inclusion criteria for these subjects will include: 1. age \<1 year, 2. male or female, 3. small for gestational age or intra-uterine growth restriction (iugr) defined by the 9th revision of the international classification for diseases or 4. prematurity as defined by the 9th revision of the international classification for diseases. exclusion criteria: * exclusion criteria include refusal or inability to provide samples of blood.
examining the risk of skin cancer in multiple sclerosis patients using fingolimod: a population-based study

Conditions: Multiple Sclerosis; Skin Cancer; Skin Cancer Melanoma; Skin Cancers - Basal Cell Carcinoma; Skin Cancer, Squamous Cell; Multiple Sclerosis (MS) - Relapsing-remitting

Summary: the goal of this retrospective observational study is to investigate the long-term safety of fingolimod in individuals with multiple sclerosis (ms), specifically focusing on the risk of developing skin cancer. the main question it aims to answer is: • does the use of fingolimod increase the incidence of skin cancer in individuals with ms compared to those using other disease-modifying therapies? participants who are new users of fingolimod or other active comparators as part of their regular medical care for ms will be included in this study. researchers will use advanced causal inference techniques to analyze healthcare data and compare the incidence of skin cancer between these groups.


Eligibility criteria:
inclusion criteria: * identified ms cohort with hospital/physician and prescription claims classified according to the international classification of disease codes and drug identification numbers respectively, using a validated case definition. this case definition requires an individual to have at least three health care encounters (any combination of inpatient encounter, outpatient encounter, or dmt dispensation) for ms in a 1-year window * ms patients who initiated and used fingolimod, natalizumab, alemtuzumab, dimethyl fumarate, or teriflunomide as monotherapy following ms identification. exclusion criteria: * pediatric (\<18 years old) ms cases. * ms cases with less than three years of baseline data before the first drug dispensation. * ms cases with skin cancer in the three-year baseline period

Keywords: multiple sclerosis and skin cancer fingolimod disease modifying therapy fty720 fingolimod and skin cancer
analgesic effect of intranasal calcitonin on patients with fractured ribs

Conditions: Rib Fractures; Pain

Summary: this study, which will be conducted at the emergency room of the sacré-cœur hospital, requires the recruitment of 60 subjects and involves some telephone follow-up. calcitonin administered as an intranasal spray is already used to relieve pain caused by broken vertebrae and we seek to determine if it can be as efficient in the case of pain caused by broken ribs.this study aims at testing the hypothesis that subjects suffering from the accidental fracture of one or more ribs will get relief through the intranasal spraying of calcitonin and/or will use less opiate medication for pain relief (a combination of oxycodone chlorhydrate and acetaminophen called percocet®).


Eligibility criteria:
inclusion criteria: * patients aged 18 or more. * accidental rib fracture (one or more) visible on a lung\\thorax radiography, or on a ct scan of the thorax, as determined by the emergency physician or the radiologist. * the rib fracture is the main cause of pain. * the patient says yes to the question "do you wish something for your pain" (the result of the quantitative assessment of the pain in not taken into consideration) or the patient has already received an analgesic before the initial assessment by the emergency physician. * the patient is seen no more than 48 hours after the accident. exclusion criteria: * the patient is already receiving sc. * allergy or intolerance to sc, oxycodone chlorhydrate or acetaminophen * active neoplasia history for at least 5 years * toxicomania history as revealed by case history * osteoporosis linked to hyperparathyroidism * patient already using opiate analgesics or other analgesics on a regular basis (excluding aspirin at doses of 325 mg or less, as a prophylactic for cardiovascular diseases and under stable posology for at least 15 days) * steroid use within the past month * pregnancy, breast feeding * non-availability of patient for telephone follow-ups or follow-up appointments.

Keywords: rib fracture pain intranasal calcitonin
effect of symbicort on hat and hdac in sputum macrophages of copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Age Matched Healthy Volunteers (Non-smokers)

Summary: the purpose of the study is to compare histone acetyltransferase (hat) and histone deacetylase (hdac) expressions and activities in induced sputum macrophages obtained from patients with moderate to severe copd and age-matched normal non-smokers


Eligibility criteria:
inclusion criteria: inclusion criteria-healthy non-smokers * non-smoking volunteer * aged 40 -75 years (age matched to copd patients) * normal spirometry (normal fev1/fvc ratio \>70% and fev1\>80% predicted) * subjects are able to give informed consent inclusion criteria-copd patients (stage ii-iii according to the gold guidelines) * current and/or ex-smokers with no less than 10 pack-year smoking history * aged 40 -75 years * fev1 greater than or equal to 30% and less than 80% of predicted (the upper value is a prostbronchodilator value) * fev1/fvc \< 70% * patients with stable copd * inhaled corticosteroid (ics) treatment, if exists, must be stopped for 2 weeks prior the study treatment * long-acting beta2-agonists and theophylline need to be stopped at least 3 days before run-in , but anti-cholinergics will be allowed throughout the study * the subjects are able to give informed consent exclusion criteria: exclusion criteria-healthy non-smokers * pregnancy, breast-feeding or planned pregnancy during the study. fertile women not using acceptable contraceptive measures, as judged by the investigator * upper respiratory infection within the last 4 weeks * subjects who have received research medication within the previous one month * subjects unable to give informed consent * any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study. exclusion criteria-copd patients * evidence of asthma * bronchodilator reversibility \> 12% * pregnancy, breast-feeding or planned pregnancy during the study. fertile women not using acceptable contraceptive measures, as judged by the investigator * patients who have had oral steroids within 8 weeks prior to the screening visit. * patients who are already on ics and in which it is considered unsafe (as judged by the investigator) to stop this treatment for the study period. * patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the screening visit. * upper respiratory infection within the last 4 weeks * subjects who have received research medication within the previous one month * subjects unable to give informed consent * any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study * patients with significant co-morbidities as judged by the investigator * any other respiratory disease, which is considered by the investigator to be clinically significant
efficacy of methylene blue mediated photodynamic therapy for primary localized cutaneous amyloidosis treatment in asians

Conditions: Lichen Amyloidosis

Summary: efficacy of methylene blue mediated photodynamic therapy for primary localized cutaneous amyloidosis treatment in asians, pilot study.


Eligibility criteria:
inclusion criteria: * patients, aged \> 18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathological findings. exclusion criteria: * those with systemic disease associated cutaneous amyloidosis * pregnancy or lactating woman * those who are allergic to urea, olive oil * those who are photosensitive to ultraviolet radiation * those who had been previously treated with any of which -medications, radiation, laser within 3 months and 1 month for topical therapy

Keywords: methylene blue photodynamic therapy primary cutaneous localized amyloidosis lichen amyloidosis
clinical study with berberine-based food supplement, artichoke extract, phytosterols, fenugreek and selectsieve® optichol

Conditions: Dyslipidemias

Summary: to evaluate the effects of a nutraceutical containing berberine-based food supplement, artichoke extract, phytosterols, fenugreek and selectsieve® optichol on lipid profile

to evaluate the effects of a nutraceutical containing berberine-based food supplement, artichoke extract, phytosterols, fenugreek and selectsieve® optichol compared to placebo on lipid profile in patients with ldl cholesterol \> 115 and \< 190 mg/dl.patients were allocated to receive 1 or 2 tablets of the nutraceutical for 12 weeks.

Eligibility criteria:
inclusion criteria: * ldl cholesterol \> 115 mg/dl and \< 190 mg/dl * primary prevention exclusion criteria: * patients with neoplastic and liver diseases, renal failure and diabetes mellitus * pregnant or breastfeeding women * hypersensitivity to any of the ingredients * therapy with lipid-lowering drugs
a study of kyphoplasty and vertebroplasty in the treatment of spine metastases

Conditions: Solid Tumors; Spine Metastasis

Summary: conventional vertebroplasty is an effective option in the treatment of bone lesions (osteoporotic and neoplastic). it is indicated as an analgesic treatment and aims at reinforcing a compressed vertebrae or at risk of fracture. the main adverse event related to vertebroplasty use is the cement leakages that might be responsible for significant clinical impairments. kyphoplasty is a recent alternative strategy of vertebroplasty, based on the insertion on balloon through the needle into the targeted vertebrae and then inflation of the balloon prior to cement injection into the space. in an osteoporotic setting, kyphoplasty allow reducing the incidence of cement leakage. to date, no data from randomized study are available in the population of cancer patients.


Eligibility criteria:
inclusion criteria: * diagnosis of cancer other than malignant hemopathies, myeloma, brain tumors, germ-cell tumors and bone sarcomas; * 2 metastatic sites or more; * spine metastasis between t1 and l5 with reduction of vertebrae of 20% at least; * indication of cementoplasty of 1 to 6 vertebrae defined by 1 of the following: * pain equal or greater than 4/10 at visual analogic scale * unstable vertebrae (sins score equal or greater than 7; * performance status of the eastern cooperative oncology group : 0, 1 or 2 exclusion criteria: * contraindication to vertebroplasty, including contraindication to cement use; * patient already treated by vertebroplasty within the past 3 months (1 patient can not be allocated twice in this study); * previous focal treatment of the targeted vertebrae (vertebroplasty, percutaneous radiofrequency, embolization); * neurological deficit due to medullar or radicular compression; * participation to another clinical trial with an analgesic intent.

Keywords: solid tumors spine metastasis vertebroplasty kyphoplasty randomization